CDH Investments
Edit

CDH Investments

https://www.cdhfund.com/
Last activity: 10.09.2026
Active
Established in 2002, CDH Investments is one of the leading alternative investment fund managers focused on China today with over US$19 billion of assets under management, as of December 31, 2019. CDH was founded by WU Shangzhi, JIAO Shuge and four other investment professionals who worked together in the direct investment department of China International Capital Corporation beginning in 1995. From its roots in private equity, CDH has expanded to become a diversified alternative asset management platform covering: Private Equity, Real Assets, Venture and Growth Capital, Mezzanine&Credit, Public Equities and Wealth Management. CDH has more than 100 investment professionals working in offices in Hong Kong, Singapore, Beijing, Shanghai and Shenzhen. CDH has invested in more than 180 companies and has helped more than 50 companies successfully list on international and China’s domestic stock exchanges. As of 2016, these companies employ more than 500,000 people. Many of them are sector leaders, and, collectively, they play an important role in China’s economy. CDH’s core principle is to create value for all of our partners, including investors and portfolio companies. We continually strive to embody this principle and make it the basis for all of our decisions. We maintain close cooperative partnerships with over 100 international and local institutional investors.
Followers
17.46K
Portfolio
4
Mentions
41
Employees: 201-500
Founded date: 2002
Investment Stage: Series D

Portfolio 4

DateNameWebsiteTotal RaisedLocation
01.09.2026VASTvast.ai$446MUnited Sta...
01.09.2026Tripo AI f...tripo3d.ai$795MChina
24.10.2025Neolixneolix.cn$629MChina
23.09.2025AusperBioausperbio.com$306M-

Mentions in press and media 41

DateTitleDescription
13.09.2026Deep Tech Dominates: Capital Floods AI Infrastructure, 3D Generative ModelsVenture capital surges into deep tech, funneling massive investments into AI infrastructure and critical "control points." Tripo AI secured $446 million for its 3D generative foundation models, highlighting a strategic pivot towar...
10.09.2026Tripo AI Lands 3 Billion Yuan, Unveils Quad-Topology ModelTripo AI, an artificial intelligence company building 3D foundation models and world models, has raised approximately 3 billion yuan (approx. $447M) across its Series B and Series B+ funding rounds, in a raise led by MPCi. The company tied ...
01.09.2026AusperBio Inks $120 Million Series C Financing SAN FRANCISCO, CA, AusperBio Therapeutics, a near-commercial biopharmaceutical company, announced the closing of its $120 million Series C financing. >> Click here for more funding data on AusperBio >> To export AusperBio fundi...
01.09.2026Tripo AI Raises Approx. 445M in Series B FundingTripo AI, a Hong Kong-based provider of a 3D-native foundation model platform for generative 3D, raised approximately $445M in Series B funding. The round was led by MPCi with participation from Perfect World, BlueFocus, SPC, Yanqu Games, T...
01.09.2026VAST Raises $446 Million in Series B & B+ To Revolutionize Generative AI 3DBuilding AI infrastructure today is ruthlessly expensive, demanding massive upfront capital just to keep the servers running. This heavy financial burden crushes most ambitious startups before they even launch. But the narrative is shifting...
01.09.2026Startup Funding News Today, September 1, 2026: VAST, Gridsight, Airbility, Kepler Aerospace & MoreA $446 million AI financing in China, a $26 million bet on overloaded electricity grids, and fresh capital for counter-drone aircraft set the tone for startup funding on September 1. Today’s 10 selected rounds span generative 3D models and ...
01.09.2026Venture Capital & Startup Funding Roundup, September 1, 2026: Andreessen Horowitz; General Catalyst, Sequoia Capital & MoreVenture investors spent the past 12 hours buying control points rather than another layer of generic AI applications. The largest deal in this edition, Tripo AI’s roughly RMB 3 billion financing, targets 3D-native foundation models and the ...
30.08.2026AusperBio Secures $120M, Propels AHB-137 to Phase 3 for Hepatitis B Functional CureAusperBio secured $120 million Series C, raising total capital to $360 million. This substantial funding accelerates its lead candidate, AHB-137, into a pivotal Phase 3 program for chronic hepatitis B. The company aggressively pursues a fun...
28.08.2026AusperBio Raises $120 Million To Push a Hepatitis B Functional CureChronic hepatitis B affects over 250 million people in the world. What’s available as the solution today can only manage the virus, it can rarely cure it. So, most patients end up depending on drugs for life. To solve this, Ausperbio raises...
28.08.2026AusperBio Raises $120 Million Series C As Total Funding Reaches $360 Million And AHB-137 Advances Through Phase 3AusperBio has closed a $120 million Series C financing to advance its chronic hepatitis B pipeline, including the Phase 3 registrational program and potential commercialization of its lead investigational therapy AHB-137. The financing brin...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In